Brokerages Set Kymera Therapeutics, Inc. (NASDAQ:KYMR) Price Target at $53.40

Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) have received an average rating of “Moderate Buy” from the eighteen analysts that are covering the stock, Marketbeat Ratings reports. Four equities research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $53.88.

Several equities analysts have recently issued reports on the company. Leerink Partners reaffirmed an “outperform” rating and set a $60.00 price target on shares of Kymera Therapeutics in a research note on Monday, September 9th. Truist Financial reiterated a “buy” rating and issued a $53.00 price target (down previously from $54.00) on shares of Kymera Therapeutics in a report on Friday, November 1st. Wolfe Research upgraded Kymera Therapeutics from a “peer perform” rating to an “outperform” rating and set a $65.00 price target on the stock in a report on Monday, August 26th. UBS Group decreased their price target on Kymera Therapeutics from $80.00 to $74.00 and set a “buy” rating on the stock in a report on Monday, November 4th. Finally, Oppenheimer raised their price target on Kymera Therapeutics from $52.00 to $56.00 and gave the company an “outperform” rating in a report on Friday, September 27th.

Insider Transactions at Kymera Therapeutics

In other news, Director Pamela Esposito sold 13,500 shares of the firm’s stock in a transaction dated Tuesday, September 17th. The stock was sold at an average price of $48.28, for a total transaction of $651,780.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. 15.82% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Kymera Therapeutics

Hedge funds have recently modified their holdings of the business. Values First Advisors Inc. acquired a new stake in shares of Kymera Therapeutics during the third quarter worth about $61,000. Quarry LP acquired a new stake in Kymera Therapeutics in the 3rd quarter valued at approximately $95,000. Mirae Asset Global Investments Co. Ltd. raised its position in Kymera Therapeutics by 27.5% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,336 shares of the company’s stock valued at $114,000 after buying an additional 504 shares during the last quarter. Comerica Bank raised its position in Kymera Therapeutics by 13.7% in the 1st quarter. Comerica Bank now owns 3,324 shares of the company’s stock valued at $134,000 after buying an additional 400 shares during the last quarter. Finally, Public Employees Retirement Association of Colorado acquired a new stake in Kymera Therapeutics in the 2nd quarter valued at approximately $139,000.

Kymera Therapeutics Stock Performance

Kymera Therapeutics stock opened at $45.05 on Wednesday. The firm has a market cap of $2.92 billion, a P/E ratio of -18.88 and a beta of 2.16. The business’s fifty day moving average is $46.32 and its two-hundred day moving average is $42.71. Kymera Therapeutics has a 52 week low of $21.20 and a 52 week high of $53.27.

Kymera Therapeutics (NASDAQ:KYMR) last posted its quarterly earnings data on Thursday, October 31st. The company reported ($0.82) EPS for the quarter, topping analysts’ consensus estimates of ($0.83) by $0.01. The company had revenue of $3.74 million for the quarter, compared to analyst estimates of $10.34 million. Kymera Therapeutics had a negative return on equity of 24.96% and a negative net margin of 191.26%. The business’s revenue was down 20.9% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.90) earnings per share. On average, equities research analysts predict that Kymera Therapeutics will post -2.79 earnings per share for the current year.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.